Therapeutic Asset Ratings

91,565 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Minocycline Stroke Disorder	Joyce Chen	P4	BB (69)
Mirabegron Asthma	Kafrelsheikh University	P4	BB (69)
Mirabegron Cirrhosis Of Liver	Kafrelsheikh University	P4	BB (69)
Mirabegron Overactive Bladder	VA Office of Research and Development	P4	BB (69)
Mirtazapine Major Depressive Disorder	King's College London	P4	BB (69)
Misoprostol Dystocia	University of Texas at Austin	P4	BB (69)
Montelukast Fabry Disease	Sanofi	P4	BB (69)
Moviprep Colorectal Cancer	Radboud University Medical Center	P4	BB (69)
Naltrexone HIV Infectious Disease	Emory University	P4	BB (69)
Nebivolol Hypertensive Disorder	Kafrelsheikh University	P4	BB (69)
Nebivolol Cirrhosis Of Liver	Kafrelsheikh University	P4	BB (69)
Nepenthe Anxiety Disorder	Istituti Clinici Scientifici Maugeri SpA	P4	BB (69)
Nepenthe Depressive Disorder	Istituti Clinici Scientifici Maugeri SpA	P4	BB (69)
Nicardipine Malignant Hypertension	Haseki Training and Research Hospital	P4	BB (69)
Olaparib Ovarian Carcinoma	Imunon	P4	BB (69)
Oliceridine Burn	University of Tennessee	P4	BB (69)
Oliceridine Respiratory Failure	University of Tennessee	P4	BB (69)
Oxcarbazepine Trigeminal Neuralgia	Abbasi Shaheed Hospital	P4	BB (69)
Oxodotreotide Digestive System Neuroendocrine Tumor, Grade 1/2	Vanderbilt-Ingram Cancer Center	P4	BB (69)
Palbociclib Breast Carcinoma	Hongmei Zheng, PhD	P4	BB (69)
Palifermin Non-Hodgkin Lymphoma	National Cancer Institute (NCI)	P4	BB (69)
Paliperidone Psychotic Disorder	Consorcio Centro de Investigación Biomédica en Red (CIBER)	P4	BB (69)
Paliperidone Schizophrenia	Sher-E-Bangla Medical College	P4	BB (69)
Palmitic Monoethanolamide Chronic Prostatitis	Clinica Urologica Molinette - Città della Saliute e della Scienza	P4	BB (69)
Pancrelipase Cystic Fibrosis	Anagram Therapeutics, Inc.	P4	BB (69)

Showing 2951 to 2975 of 42,286 assets

PreviousPage 119 of 1692Next